Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
COYA 
Coya Therapeutics, Inc. Common Stock (COYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: COYA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.64
1 Year Target Price $16.64
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.99% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 112.23M USD | Price to earnings Ratio - | 1Y Target Price 16.64 |
Price to earnings Ratio - | 1Y Target Price 16.64 | ||
Volume (30-day avg) 5 | Beta 0.26 | 52 Weeks Range 4.65 - 10.24 | Updated Date 08/29/2025 |
52 Weeks Range 4.65 - 10.24 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate 0.13 | Actual -0.36 |
Profitability
Profit Margin - | Operating Margin (TTM) -3920.47% |
Management Effectiveness
Return on Assets (TTM) -38.53% | Return on Equity (TTM) -63.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 82467965 | Price to Sales(TTM) 265.03 |
Enterprise Value 82467965 | Price to Sales(TTM) 265.03 | ||
Enterprise Value to Revenue 194.75 | Enterprise Value to EBITDA -6.21 | Shares Outstanding 16725100 | Shares Floating 12631952 |
Shares Outstanding 16725100 | Shares Floating 12631952 | ||
Percent Insiders 7.12 | Percent Institutions 27.03 |
Upturn AI SWOT
Coya Therapeutics, Inc. Common Stock
Company Overview
History and Background
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative therapies for neurodegenerative diseases, with a particular focus on regulatory T cells (Tregs). Founded in 2020, Coya is leveraging its proprietary platform to develop disease-modifying approaches for diseases like ALS, frontotemporal dementia (FTD), and multiple sclerosis (MS).
Core Business Areas
- Therapeutic Development: Focuses on developing and testing novel therapies for neurodegenerative diseases using Treg technology.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its therapeutic candidates.
- Proprietary Technology Platform: Develops and refines its proprietary Treg platform for enhanced therapeutic potential.
Leadership and Structure
Coya Therapeutics is led by a team of experienced biotechnology executives and scientists. Dr. Howard Berman serves as CEO. The organizational structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- COYA 101: An autologous Treg therapy for Amyotrophic Lateral Sclerosis (ALS). Currently in clinical trials. Competitors include Biogen (Tofersen), Amylyx Pharmaceuticals (Relyvrio), Mitsubishi Tanabe Pharma America (Radicava). Market share is currently 0 as it is an investigational product.
- COYA 206: An anti-IL-6 monoclonal antibody designed to enhance Treg function for neurodegenerative diseases. Pre-clinical stage. Competitors include Roche (Actemra), Sanofi (Kevzara). Market share is currently 0 as it is an investigational product.
Market Dynamics
Industry Overview
The neurodegenerative disease therapeutics market is large and growing, driven by an aging population and increasing prevalence of conditions like ALS, FTD, and MS. Significant unmet medical need exists.
Positioning
Coya Therapeutics is positioned as an innovator in Treg-based therapies for neurodegenerative diseases. Its competitive advantage lies in its proprietary platform and focus on disease modification.
Total Addressable Market (TAM)
The total addressable market for neurodegenerative disease therapies is estimated to be in the tens of billions of dollars. Coya's positioning within this TAM is based on its ability to address the underlying immune dysfunction in these diseases.
Upturn SWOT Analysis
Strengths
- Proprietary Treg platform technology
- Experienced management team
- Clinical-stage pipeline
- Focus on disease-modifying therapies
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Relatively small company size
- Competition from larger pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other neurodegenerative diseases
- Orphan drug designation
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- BIIB
- AMRX
- MTLKY
- LLY
- ABBV
Competitive Landscape
Coya's competitive advantage lies in its Treg technology, but it faces competition from larger, more established pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by the progress of its clinical trials and securing funding. The company has been developing its Treg platform.
Future Projections: Future growth is dependent on the success of clinical trials and partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing COYA 101 into a Phase 2 clinical trial and developing COYA 206.
Summary
Coya Therapeutics is a clinical-stage biotech company with a promising Treg-based platform for neurodegenerative diseases. Its future hinges on the success of its clinical trials, particularly COYA 101. While the company possesses innovative technology and an experienced team, it faces financial challenges, regulatory hurdles, and competition from larger players. Coya must continue to demonstrate clinical efficacy and secure funding to achieve its goals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on your own research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coya Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-12-29 | CEO & Director Dr. Arun Swaminathan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://coyatherapeutics.com |
Full time employees 8 | Website https://coyatherapeutics.com | ||
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, the company's pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.